NCT05527626 Chronic Kidney Disease - REAL Life Study in Alsace
| NCT ID | NCT05527626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Chronic Kidney Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-02-17 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-02-17 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic kidney disease (CKD) is a public health problem and affects about 10% of the world's adult population with a constantly increasing incidence. The approach to CKD in France is centered on access to replacement therapy (dialysis, renal transplantation), the cost of which amounts to 4 billion euros (data from the REIN registry). Real-life data are essential to specify the characteristics of patients with chronic kidney disease and the factors associated with the evolution of CKD and the occurrence of complications in order to improve the management of CKD before the suppletion stage. Since October 2019, CKD at the severe stage (stage 4) and at the non-dialysis end stage (stage 5) is subject to an annual flat fee (Article L. 162-22-6-2 of the Social Security Code). The reimbursement of these lump sums by the health insurance is subject to the collection and transmission of certain medical data by the establishments.
Eligibility Criteria
Inclusion criteria: * Major subject (≥18 years) * Subject included in the MRC package (GFR \<30 ml/min/1.73 m2) * Subject who has not expressed opposition, after information, to the reuse of his or her data for the purpose of this research Exclusion criteria: \- Subject having expressed his opposition to participate in the study
Contact & Investigator
Peggy PERRIN, MD
PRINCIPAL INVESTIGATOR
Service Néphrologie-Dialyse-Transplantation - CHU de Strasbourg - France
Frequently Asked Questions
Who can join the NCT05527626 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05527626 currently recruiting?
Yes, NCT05527626 is actively recruiting participants. Contact the research team at peggy.perrin@chru-strasbourg.fr for enrollment information.
Where is the NCT05527626 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT05527626 clinical trial?
NCT05527626 is sponsored by University Hospital, Strasbourg, France. The principal investigator is Peggy PERRIN, MD at Service Néphrologie-Dialyse-Transplantation - CHU de Strasbourg - France. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.